Small-cap Week, May 23

Tungsten, Zytronic, Quantum Pharma and Mar City featured

Reckitt faces regulatory friction on K-Y

UK watchdog raises concern over impact on competition

Hikma founder Samih Darwazah dies at 85

Palestinian who built group into Arab world’s biggest drugmaker, joining blue-chip FTSE 100 index

Gravity Fitness First club

Penthouse gym to cater for high-flyers

Fitness First opens facility for Singapore’s wealthy

Circassia

Circassia deal signals UK biotech revival

Share placement shows fresh appetite for life-science drug groups

Endo Pharmaceuticals Pennsylvania headquarters

Endo/Par: too much of a good thing

The pharma group has rebuilt itself with deals but the latest is a big bite

Endo to buy Par in $8bn deal

TPG has roughly quintupled its $1.9bn investment

D27P5M Studio shot of young woman working in office covered with adhesive notes. Image shot 2012. Exact date unknown.

Women feel under more stress at work

Willingness to acknowledge pressure is a factor

Big Pharma’s antibiotic resistance

Profit cannot be sole motive of an industry founded on making people better, writes Anjana Ahuja

Circassia

Circassia lauds life-science investment

Invesco and Neil Woodford back anti-allergy specialist’s offering

Brent Saunders, Actavis: Botox initiation

Dealmaking pharma CEO ‘ambushed’ into an extreme product test

Week in Review, May 16

Airbus crash inquiry; car recalls, Bombardier and cancer drugs also in the news

Drugs to watch in fight against cancer

Treatments turn the body’s immune system into a weapon

High hopes for ‘first cannabis pharmacy’

Oil and hand cream products use hemp from Czech Republic

New drugs way to avoid an antibiotic apocalypse

Pharmaceutical industry needs incentives to overcome market failure

China’s vitamin market harder to crack

Producers such as Amway and Pfizer face increasing competition from locals such as By-Health

Horses for courses to gee up interactions

An equine away day promises insights into how we behave with colleagues and clients

Big pharma risks backlash on antibiotics

Jim O’Neill warns industry on drug resistance

US drug ‘super spenders’ cost $52bn

Report finds big rise in patients with bills of more than $50,000

Pharma M&A: Taking stock

When shares become a dealmaking currency, be careful

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE